Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Harmony Biosciences Holdings, Inc.

Harmony Biosciences is a biopharmaceutical company focused on developing and delivering medicines for patients with unmet medical needs, particularly in the area of narcolepsy.  The self-described patient-focused drug development model uses patient insights to inform clinical research programs.

COM:HARMONYBIOSCIENCES

Harmony Biosciences

Last Close

33.23

22/11 21:00

Market Cap

1.90B

Beta: -

Volume Today

487.85K

Avg: -

Financials Not Available